Lansen Pharmaceutical : VOLUNTARY ANNOUNCEMENT IN RESPECT OF THE INFLUENCE OF THE NOVEL CORONAVIRUS

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

LANSEN PHARMACEUTICAL HOLDINGS LIMITED

朗生醫藥控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 503)

VOLUNTARY ANNOUNCEMENT

IN RESPECT OF THE INFLUENCE OF THE NOVEL CORONAVIRUS

This announcement is made by Lansen Pharmaceutical Holdings Limited (the "Company", together with its subsidiaries shall be referred to as the "Group") on a voluntary basis in respect of the influence of the Novel Coronavirus to the Group's business operation.

At present, production of all of the Group's plants is either on hold or preparing to gradually resume production within the next 7-10 days, subject to the further development of the epidemic and government advice or restrictions. Accordingly, there is a risk that these restrictions, if prolonged, may further limit production of products and/or sales in hospitals which may have an adverse impact on the Group's operation and financial performance. At this stage it is too early to gauge whether there will be an impact of any significance on the Group's operation for the year 2020.

The Board will continue to assess the impact of the Novel Coronavirus on the Group's operation and financial performance and closely monitor the Group's exposure to the risks and uncertainties in connection with the epidemic. The Group will take appropriate measures as necessary and make further announcements in due course.

Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board

Lansen Pharmaceutical Holdings Limited

Wu Zhen Tao

Chairman

Hong Kong, 11 February 2020

As at the date of this announcement, the executive managing Director is Mr. Chen Li; the non-executive Directors are Mr. Wu Zhen Tao, Mr. Stephen Burnau Hunt and Ms. Liu Xuezi; the independent non-executive Directors are Mr. Chan Kee Huen, Michael, Mr. Fritz Heinrich Horlacher and Mr. Yeung Tak Bun, Allen.

1